<DOC>
	<DOCNO>NCT03063944</DOCNO>
	<brief_summary>This phase I trial study side effect best dose STAT inhibitor OPB-111077 give together decitabine treat patient acute myeloid leukemia respond treatment newly diagnose ineligible intensive chemotherapy . STAT inhibitor OPB-111077 decitabine may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>STAT Inhibitor OPB-111077 Decitabine Treating Patients With Acute Myeloid Leukemia That Is Refractory Newly Diagnosed Ineligible Intensive Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety tolerability STAT inhibitor OPB-111077 ( OPB-111077 ) combination decitabine . SECONDARY OBJECTIVES : I . To describe preliminary efficacy OPB-111077 combination decitabine patient acute myeloid leukemia ( AML ) . II . To measure adenosine triphosphate ( ATP ) generation perform metabolomics patient AML receive OPB-111077 decitabine . III . To assess apoptosis proliferation assay patient AML receive OPB-111077 decitabine .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients must histologic evidence high risk acute myeloid leukemia define one following : Primary refractory nonM3 AML ** Evidence leukemia therapy , opinion investigator , would appropriate therapy OPB111077 decitabine Newly diagnose nonM3 AML eligible intensive induction chemotherapy Subjects must Eastern Cooperative Oncology Group ( ECOG ) performance status 2 less Subjects must life expectancy least 4 week Subjects must able consume oral medication Subjects must recover toxic effect prior chemotherapy &lt; grade 1 ( except alopecia ) Creatinine = &lt; 2.0mg/dL Total bilirubin = &lt; 2 x upper limit normal ( ULN ) Serum glutamate pyruvate transaminase ( SGPT ) alanine aminotransferase ( ALT ) = &lt; 2 x ULN Negative pregnancy test woman childbearing potential Patients must able sign consent willing able comply schedule visit , treatment plan laboratory testing Subjects FAB M3 ( ( 15 ; 17 ) ( q22 ; q21 ) [ PMLRARalpha ] ) eligible Subjects must receive chemotherapy agent ( except hydroxyurea ) ; intrathecal methotrexate cytarabine permissible Subjects must receive growth factor , except erythropoietin Subjects `` currently active '' second malignancy , nonmelanoma skin cancer , carcinoma situ cervix , resect incidental prostate cancer ( stag pT2 Gleason score = &lt; 6 postoperative prostatespecific antigen [ PSA ] &lt; 0.5 ng/mL ) , adequately treat carcinomainsitu ineligible ; patient consider `` currently active '' malignancy complete therapy free disease &gt; = 1 year Subjects uncontrolled high blood pressure , unstable angina , symptomatic congestive heart failure ( New York Heart Association [ NYHA ] class 3 ) , myocardial infarction within past 6 month serious uncontrolled cardiac arrhythmia eligible Subjects severe concurrent disease judgment investigator would make patient inappropriate entry study ineligible Subjects must evidence active leukemia central nervous system ( CNS ) Subjects must receive investigational agent within 30 day study entry Subjects must pregnant breastfeeding ; pregnancy test must obtain female childbearing potential ; pregnant lactating patient ineligible study ; male woman childbearing potential may participate unless agree use effective contraceptive method ( define hormonal contraceptive , intrauterine device , surgical contraceptive , condom ) Subjects uncontrolled infection eligible ; patient must active infection control ; fungal disease must stable least 2 week study entry Subjects bacteremia must document negative blood culture prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>